



Right5

Clinically Validated Personalised Medication Dosing

A new dosing platform for the whole world

The right patient

The right drug

The right time

The right dose

The right route

2022, Estonia







Growing Global problems

Many drugs have a **narrow therapeutic window** - there is very little difference between the dose that produces positive effects on the dose that is toxic. Thus, there is a **risk of underdosing as well as toxic side effects**. Side effects can be very serious, such as kidney or liver failure, or loss of consciousness. Underdosing, in turn, is often associated with insufficient effect, i.e., that too low a dose of drug does not achieve the desired therapeutic result.

Studies have shown that people differ from each other and that the concentrations of medicines vary from person to person after the same dose. The Food and Drug Administration 2017 estimates that just in the US, 1.3 million people are injured by medication errors annually in the U.S (<https://www.aarp.org/health/drugs-supplements/info-2017/medication-errors-rise-fd.html>) .



We Are All Molecularly Personalized



TREATMENT DECISION BASED ON DOSOPT SOFTWARE AND HAS A STRONG THERAPEUTIC EFFECT.



Our Solution


Right5's ambition is to launch easy-to-use patients and doctors (B2C) as well as hospitals (B2B) precision medicine dosing platform with clinically validated algorithms to the global market.

By the end of 2023-2Q 2024, the Right5 platform will consist of four products, one of which has been clinically validated and three of which are based on Therapeutic Drug Monitoring (TDM):

- **VANCOMYCIN** – Intravenous antibiotics for Gram-positive microorganisms. The first line antibiotics for treatment of MRSA (methicillin resistant S.aureus) and MRSE (methicillin resistant S.epidermidis) worldwide.
- **LOW MOLECULAR WEIGHT HEPARIN (TDM)** – Blood-thinning agent.
- **CYCLOSPORINE (TDM)** – Immunosuppressive agent.
- **VALPROIC ACID (TDM)** – Widely used anticonvulsant drug, effective for most forms of epilepsy.



DosOpt dosing calculator works **24/7/365** With SaaS & PaaS Architecture



Diagnostics

The Right5 calculator analyzes the entered patient blood marker data. Detailed side-by-side analysis of complex components identifies all side effects, defects and anomalies.

Autopilot prescriptions

The software-based (future (2025) AI-based) dosing operator will ensure that all medications diagnoses are available in a timely and continuous manner.



The First Customer & Service Decision Chain

Our first clients will be major Estonian hospitals - The single scientific clinic in Estonia - The Tartu University Hospital and The North-Estonian Regional Hospital.

In outside of basic country, we will find the first foreign clients thanks to the existing network and pre-cooperation from GB and Sweden.

&


An initial recommendation to use the Right5 service (first license) will be made on the advice of patients treatment doctors. The proposal must be approved by the hospital's chief medical officer.

The final decision must be approved by the hospital board.




Cross-device

We integrate the results of research and technological development into the software core and algorithm being developed. We interface payment solutions and a user interface that enables online sales with the core. We are creating smart device versions for Android and iOS.





Market & Service Positioning




Expected Growth



MEUR

Total Growth



KEY NOTES

- Estimated break-even: 2025.
- The 1st quarter with 1,0 MEUR Revenue: III/2026.
- The 1st quarter with 1,0 MEUR Profit: 2027.
- Team growth: from 17 (Jun'22) to 35 (Dec'25) to 45 (Dec'27).




Global Market

The global therapeutic drug monitoring market is projected to reach USD 2.7 billion by 2026 from USD 1.6 billion in 2020, at a CAGR of 9.4% during the forecast period

(<https://www.marketsandmarkets.com/Market-Reports/therapeutic-drug-monitoring-market-155350443.html>)

Attractive Opportunities in the Therapeutic Drug Monitoring Market





Future Developments

We are launching **an over-the-counter calculator** for everyone to use (2024)

Dosing of **all antibiotics** used worldwide based on **inflammatory markers** (2024 – 2025)

To become **the world's best** precision dosing platform **for neonates and children** (2024 - ...)

We launch a **pharmacogenetic report** support for the Right5 calculator (2024-2025)

We scale up the software-based drug portfolio to **50 preparations** (2026)

TO BECOME THE MOST WIDELY USED PRECISION DOSING PLATFORM FOR ALL HOSPITALS IN THE WORLD!

Artificial intelligence-based outpatient treatment solutions - no longer drug-based dosing, but **patient- and diagnosis-based** dosing, where the platform offers a complete solution of the treatment scheme, when the patient's phenotypic and genotypic data, multiple biomarkers, concomitant medication and other diagnostic data are included. (2025-2028)



Competitors

US based Competitors:



EU based Competitors (there are no business models operating on a commercial basis):

- [TDMX](#)
- [NextDose](#)
- [EzeChiel](#)
- [Adult and Pediatric Kinetics](#) (APK) from RxKinetics
- [BestDose](#)



Right5 competitive advantages

- Clinically validated vancomycin
- Best possible algorithm compliance with **European treatment practices and standards** (somewhat different from US standards)
- Plans to add **pharmacogenetic** query as a service
- **Cost advantage** - subsequent clinical validation of the portfolio with other drugs (such as immediate vancomycin) **is about 10 times cheaper than in other European and North-Americas countries.**
- Our scientific partner The University of Tartu is one of the oldest (1632) centers of medical sciences in the Baltics and Scandinavia.
- Estonia is one of the world's leading countries in technological innovation, including bioinformatics solutions.



THE TEAM



Prof Irja Lutsar

Chair of the Board
Research & Development
Executive, Founder, Partner
Professor of Medical Microbiology,
University of Tartu

[FULL CV \(ETIS\)](#)



Prof Tuuli Metsvaht

Member of the Board
Clinical Trial Lead and Dosing
Optimization, Founder,
Partner
Professor of Intensive Care Pediatrics,
University of Tartu

[FULL CV \(ETIS\)](#)



Dr Hiie Soeorg, PhD

Senior Statistics and Back-End
Engineer, Founder
Scientist of Medical Microbiology,
University of Tartu

[FULL CV \(ETIS\)](#)



Raivo Metsvaht

Senior Infrastructure and Full
Stack Engineer

Engineer, University of Tartu

[FULL CV \(ETIS\)](#)



Margus Maidla, MBA

Member of the Board
CEO&CFO, Founder, Partner

[https://www.linkedin.com/in/margus-
maidla-20680a44/](https://www.linkedin.com/in/margus-maidla-20680a44/)



THE TEAM



Developments Storyline

Academic level – pre-seed stage:


- More than ten years of pharmacokinetic research and dozens of scientific publications in high-impact medical journals. The main research institution has been the University of Tartu.
- An overview of the ten most important publications can be found on [our website](#).
- Until the start generation of the business model, approx 3.4 M EUR of funding from various research grants has been invested in the preliminary research works of the project.
- 2018. Launch of the academic dosing calculator (not available in clinical practice)

Business level – seed and future stages:

- 2019. Establishment of the business development team. 1. Apr. 2022. founded OÜ Right5.
- 2019 - 2021 Preparation a business model and business model generation
- Q2 2022 – closing end of Q3 2022 – Seed funding investment round amount EUR 300,000 & Q3 – Q4 2022 grant application EUR 500,000 from the applied research program of the Estonian Enterprise Development Foundation
- Q 2024 - launch of a commercial basis medication calculator and opening of a new start-up stage round for further development and market conquest



Risks Chart - The Team is Constantly Thinking About Solutions to These Issues





Seed Round Concept

In summary, the schedule of the financing of the first stage of development consists of two parts:

- EUR 300,000 for seed funding (private equity) investment to raise equity capital
- EUR 500,000 from the grant of the applied research program of the Estonian Enterprise Development Foundation
- In total, the budget of the first development phase (commercial prototype) is approx EUR 750,000 + reserv.



Investment

Call to current round:

Q3 2022 – closing end of Q4 2022 – Seed Funding Investment round amount EUR 300,000 (minimum investment ticket size by 25,000). Equity offered: 15%.

Next investment rounds:

Q2 or Q3 2024 – 3-5 M EUR (or bridge-funding 1-1,5 M EUR for public co-funding) – increasing the portfolio of drugs to 50 treatments (10 clinically validated), pharmacogenetic support, launch of an over-the-counter medicine calculator

2025 – 3-5 M EUR (or bridge-funding 1-1,5 M EUR for public co-funding) – diagnosis-based dosing on artificial intelligence



Contacts

Our Web - <https://right5.eu/en/>

Prof Irja Lutsar – Chair of the Board, Research & Development Executive, Founder, Partner

+372 737 4171 irja.lutsar@right5.eu

Margus Maidla – Member of the Board, CEO & CFO, Founder, Partner

+372 5660 2129 margus.maidla@right5.eu

Call to action - let's save the lives!

“Sola dosis facit venenum”

Every drug is a poison, it all depends on the dose!

Paracelsus (1493 – 1541)